Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosuvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PDE6D | O43924 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosuvastatin SCHEMBL28393539 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240432 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL32686257 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL41433 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL2520 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL3938301 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL154400 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240433 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL8268193 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL29722976 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091390-B2 | Rosuvastatin calcium and process for producing intermediate thereof | API CORPORATION (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-3648756-A1 | STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019010146-A1 | STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2019-01-10 | — | — | WO | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-2602249-B1 | Synthesis of rosuvastatin by means of co-crystals | ITALIANA SINT SPA (IT) | 2015-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091390-B2 | Rosuvastatin calcium and process for producing intermediate thereof | HMGCR, COASY, PCSK9 | HMGCR 1/4885ALDH1A1 2111/4885CYP3A4 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.